Hydrochloric Acid → 4-[2-(5-bromopyrimidin-2-yloxy)-1,1-dimethylethyl]-N-{6-[2-(5-bromopyrimidin-2-yloxy)ethoxy]-5-(4-methylphenyl)pyrimidin-4-yl}benzenesulfonamide

HRID 1082295

Reaktionsgleichung

Reaktionsgleichung von HRID 1082295
[H-].[Na+].[OH:3][CH2:4][C:5]([C:8]1[CH:13]=[CH:12][C:11]([S:14]([NH:17][C:18]2[C:23]([C:24]3[CH:29]=[CH:28][C:27]([CH3:30])=[CH:26][CH:25]=3)=[C:22]([O:31][CH2:32][CH2:33][OH:34])[N:21]=[CH:20][N:19]=2)(=[O:16])=[O:15])=[CH:10][CH:9]=1)([CH3:7])[CH3:6].[Br:35][C:36]1[CH:37]=[N:38][C:39](Cl)=[N:40][CH:41]=1.Cl>CC(N(C)C)=O.O1CCCC1>[Br:35][C:36]1[CH:37]=[N:38][C:39]([O:3][CH2:4][C:5]([C:8]2[CH:13]=[CH:12][C:11]([S:14]([NH:17][C:18]3[C:23]([C:24]4[CH:25]=[CH:26][C:27]([CH3:30])=[CH:28][CH:29]=4)=[C:22]([O:31][CH2:32][CH2:33][O:34][C:39]4[N:40]=[CH:41][C:36]([Br:35])=[CH:37][N:38]=4)[N:21]=[CH:20][N:19]=3)(=[O:15])=[O:16])=[CH:10][CH:9]=2)([CH3:7])[CH3:6])=[N:40][CH:41]=1

Komponenten

7

Edukt 4

HCID 313Hydrochloric AcidHCID 24758Sodium hydrideHCID 6066655-Bromo-2-chloropyrimidineHCID 196895154-(2-hydroxy-1,1-dimethylethyl)-N-{6-[2-hydroxyethoxy]-5-(4-methylphenyl)pyrimidin-4-yl}benzenesulfonamide

Produkt 1

HCID 196895184-[2-(5-bromopyrimidin-2-yloxy)-1,1-dimethylethyl]-N-{6-[2-(5-bromopyrimidin-2-yloxy)ethoxy]-5-(4-methylphenyl)pyrimidin-4-yl}benzenesulfonamideAusbeute 33,8 %

Reagenzien, Katalysatoren, Lösungsmittel 2

HCID 8028TetrahydrofuranLösungsmittel2×HCID 31374DimethylacetamideLösungsmittel2×

Versuchsvorschrift

To a suspension of sodium hydride (65 mg) in dimethylacetamide (0.5 ml) and tetrahydrofuran (0.5 ml) is added dropwise a solution of 4-(2-hydroxy-1,1-dimethylethyl)-N-{6-[2-hydroxyethoxy]-5-(4-methylphenyl)pyrimidin-4-yl}benzenesulfonamide (135 mg) in dimethylacetamide (2 ml) and THF (2 ml) solution over period of 5 minutes at room temperature, and thereto is added 5-bromo-2-chloropyrimidine (399 mg). The mixture is stirred at room temperature for 6 days. The reaction mixture is acidified with cold diluted hydrochloric acid, and extracted with ethyl acetate. The organic layer is washed with water and saturated brine, dried over anhydrous sodium sulfate, and evaporated to remove the solvent. The oily residue is purified by silica gel column chromatography (solvent; chloroform/ethyl acetate=100:1), and evaporated to remove the solvent. The resulting crude crystals are recrystallized from methylene chloride/isopropyl ether to give 4-[2-(5-bromopyrimidin-2-yloxy)-l, 1 -dimethylethyl]-N-{6-[2-(5-bromopyrimidin-2-yloxy)ethoxy]-5-(4-methylphenyl)pyrimidin-4-yl}benzenesulfonamide (77 mg) as colorless crystals.

Aufarbeitung

  1. extractionextracted with ethyl acetate
  2. washThe organic layer is washed with water and saturated brine
  3. dry with materialdried over anhydrous sodium sulfate
  4. customevaporated
  5. customto remove the solvent
  6. customThe oily residue is purified by silica gel column chromatography (solvent; chloroform/ethyl acetate=100:1)
  7. customevaporated
  8. customto remove the solvent
  9. customThe resulting crude crystals are recrystallized from methylene chloride/isopropyl ether

Quellen und Nachweise

ORD-Eintrag
ord-51a8de4eecfb44648a9644ea571af97f
Quelldatensatz
uspto-grants-1996_12
Patentnummer
US05589478

Verknüpfte Notizen

Wird geladen…